ストックスクリーナーアプリを入手
4.20
3.06%
0.11
前日終値:
$4.09
開ける：
$4.11
24時間の取引高:
387.14K
Relative Volume:
0.21
時価総額：
$299.05M
収益：
$26.87M
当期純損益:
$-137.06M
株価収益率:
-2.2009
EPS:
-1.9083
ネットキャッシュフロー:
$-125.25M
1週間 パフォーマンス:
-0.82%
1か月 パフォーマンス:
+60.27%
6か月 パフォーマンス:
+219.32%
1年 パフォーマンス:
+190.69%
1日の値動き範囲:
$4.01
$4.32
1週間の範囲:
$3.885
$4.34
52週間の値動き範囲:
$1.13
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
名前
Zentalis Pharmaceuticals Inc
セクター
電話
(858) 263-4333
住所
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
4.201 | 291.15M | 26.87M | -137.06M | -125.25M | -1.9083 |
VRTX
Vertex Pharmaceuticals Inc
|
427.40 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
708.35 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.97 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.93 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.09 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | 再開されました | Wells Fargo | Equal Weight |
| 2024-08-12 | アップグレード | Wedbush | Underperform → Neutral |
| 2024-06-20 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-06-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | ダウングレード | Wedbush | Neutral → Underperform |
| 2024-06-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 開始されました | Cowen | Outperform |
| 2022-04-06 | 開始されました | Wells Fargo | Overweight |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-29 | 開始されました | Oppenheimer | Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-01-20 | 開始されました | Wedbush | Outperform |
| 2020-09-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-28 | 開始されました | Guggenheim | Buy |
| 2020-04-28 | 開始されました | Jefferies | Buy |
| 2020-04-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Zentalis Pharmaceuticals Inc (ZNTL) 最新ニュース
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zentalis hire gets 26,000 stock options at $4.09 a share - Stock Titan
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Zentalis (ZNTL) schedules 2026 virtual meeting on directors, auditor and executive pay - Stock Titan
ZNTL Technical Analysis | Trend, Signals & Chart Patterns | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Abstract Acceptance at - GlobeNewswire
Ovarian cancer drug combo data lands June ASCO presentation - Stock Titan
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target - Insider Monkey
ZNTL: Zentalis Presents Promising Data on Azenosertib at AACR 20 - GuruFocus
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space? - Barchart.com
Zentalis presents preclinical data on cancer drug azenosertib By Investing.com - Investing.com Canada
Zentalis Highlights New Azenosertib Data in Breast Cancer - TipRanks
Zentalis Pharmaceuticals Presents Promising Preclinical Data on Azenosertib in Triple-Negative Breast Cancer and Insights on Cyclin E1-Positive Ovarian Cancer at AACR 2026 - Quiver Quantitative
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 - ChartMill
Zentalis (Nasdaq: ZNTL) unveils azenosertib TNBC and Cyclin E1 ovarian cancer data at AACR 2026 - Stock Titan
In resistant breast cancer mice, Zentalis drug drove 7 of 8 complete responses - Stock Titan
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - ADVFN
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages - MarketBeat
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance
Guggenheim Increases Zentalis Price Target, Sparking Investor Interest - timothysykes.com
Zentalis Stock Jumps as Guggenheim Lifts Price Target on Cancer Program Success - StocksToTrade
Zentalis Pharmaceuticals: Price Target Boost Sparks Speculative Momentum - timothysykes.com
Is Zentalis Pharmaceuticals (NASDAQ:ZNTL) In A Good Position To Deliver On Growth Plans? - Moomoo
What's Behind The Surge In Zentalis Stock? - Sahm
Jefferies raises Zentalis stock price target on ovarian cancer trial data - Investing.com Canada
This small-cap biotech stock just hit a near 22-month high – but this analyst still expects another 56% rally - MSN
What's behind the surge in Zentalis stock? - MSN
Today's Analyst Rating Update for ZNTL: Buy Rating Maintained wi - GuruFocus
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00 - MarketBeat
H.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection By Investing.com - Investing.com Canada
Azenosertib Shows Promising Results in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer: Zentalis Advances Registration-Intent Trials - Minichart
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - Bitget
Zentalis Advances Azenosertib Dose in DENALI Phase 2 - TipRanks
Zentalis Selects 400mg QD 5:2 Azenosertib Dose for Pivotal Ovarian Cancer Study - National Today
Zentalis selects 400mg dose for ovarian cancer drug trial By Investing.com - Investing.com UK
Zentalis selects 400mg QD 5:2 as pivotal azenosertib dose; DENALI topline due YE2026 - TradingView
Azenosertib 400mg dose to anchor Zentalis (NASDAQ: ZNTL) late-stage ovarian cancer trials - Stock Titan
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib - GlobeNewswire
Is Zentalis Pharmaceuticals (ZNTL) Stock a Value Play | Price at $2.69, Up 2.28%Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Lào Cai
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals PAO sells $7.8k in stock - Investing.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Two new Zentalis hires get stock options priced at $2.57 - Stock Titan
ZNTL PE Ratio & Valuation, Is ZNTL Overvalued - Intellectia AI
Here's What to Expect From West Pharmaceutical's Next Earnings Report - Barchart.com
Zentalis Pharmaceuticals Inc (ZNTL) 財務データ
収益
当期純利益
現金流量
EPS
Zentalis Pharmaceuticals Inc (ZNTL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 09 '26 |
Sale |
2.39 |
335 |
802 |
33,332 |
| Vultaggio Vincent | PAO and PFO |
Feb 06 '26 |
Sale |
2.43 |
29,951 |
72,772 |
156,779 |
| Vultaggio Vincent | PAO and PFO |
Feb 10 '26 |
Sale |
2.42 |
6,894 |
16,699 |
146,506 |
| Vultaggio Vincent | PAO and PFO |
Feb 09 '26 |
Sale |
2.39 |
3,379 |
8,086 |
153,400 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 06 '26 |
Sale |
2.43 |
7,866 |
19,112 |
80,022 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 09 '26 |
Sale |
2.39 |
889 |
2,127 |
79,133 |
| Vultaggio Vincent | PAO and PFO |
Feb 02 '26 |
Sale |
2.55 |
2,540 |
6,477 |
187,286 |
| Vultaggio Vincent | PAO and PFO |
Feb 03 '26 |
Sale |
2.52 |
556 |
1,398 |
186,730 |
| WALTERS GROUP | 10% Owner |
Dec 31 '25 |
Buy |
1.20 |
6,459,973 |
7,751,968 |
13,509,973 |
| Matrix Capital Management Comp | 10% Owner |
Dec 15 '25 |
Sale |
1.33 |
7,500,000 |
9,975,000 |
6,459,973 |
0.83%
2.04%
大文字化:
|
ボリューム (24 時間):